Evidence map›Paper›PMID 34895175›Full record

ArticleBMC psychiatry2021

Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia.

Feyissa Challa, Tigist Getahun, Meron Sileshi, Zeleke Geto, Teshome S Kelkile, Sintayehu Gurmessa, Girmay Medhin, Miraf Mesfin, Melkam Alemayehu, Tigist Shumet and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Feyissa ChallaNational References Laboratory for Clinical Chemistry, Ethiopian Public Health Institute, Gulelle Arbegnoch Street (the former Pasteur Institute): Gulele Sub City, Addis Ababa, Ethiopia. Feyissawaka@gmail.com.
Tigist GetahunNational References Laboratory for Clinical Chemistry, Ethiopian Public Health Institute, Gulelle Arbegnoch Street (the former Pasteur Institute): Gulele Sub City, Addis Ababa, Ethiopia.
Meron SileshiNational References Laboratory for Clinical Chemistry, Ethiopian Public Health Institute, Gulelle Arbegnoch Street (the former Pasteur Institute): Gulele Sub City, Addis Ababa, Ethiopia.
Zeleke GetoDepartment of Biomedical Science, College of Medicine and Health Science, Wollo University, Dessie, Wollo, Ethiopia.
Teshome S KelkileHorizon Health Network, Fredericton, NB, Canada.
Sintayehu GurmessaDepartment of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Girmay MedhinAklilu Lemma Institute of Pathobiology Addis Ababa University, Addis Ababa, Ethiopia.
Miraf MesfinDepartment of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Melkam AlemayehuDepartment of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Tigist ShumetNational References Laboratory for Clinical Chemistry, Ethiopian Public Health Institute, Gulelle Arbegnoch Street (the former Pasteur Institute): Gulele Sub City, Addis Ababa, Ethiopia.
Anwar MulugetaAustralian Centre for Precision Health, University of South Australia, Adelaide, Australia.
Desalegn BekeleDepartment of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Christina P C BorbaBoston University School of Medicine, Boston, MA, USA.
Claire E OppenheimBoston University School of Medicine, Boston, MA, USA.
David C HendersonBoston University School of Medicine, Boston, MA, USA.
Abebaw FekaduDepartment of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Anna CarobeneLaboratory Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Solomon TeferraDepartment of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Funding

Medical Research Council MR/M025470/1
6 · The paper itself

Abstract

backgroundGlobally, the prevalence of metabolic syndrome (MetS) is higher among patients with schizophrenia than the general population, and this leads to higher morbidity and mortality in this population. The aim of this study was to investigate the MetS prevalence among patients with schizophrenia in Ethiopia.

methodsWe conducted a cross-sectional analysis of baseline data of 200 patients with schizophrenia recruited from Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Lipid profile and blood glucose levels were measured using Roche Cobas 6000 clinical chemistry analyzer. The prevalence of MetS was assessed based on National Cholesterol Education Program Adult Treatment Panel III criteria. Patients' demographic information, clinical and laboratory data, lifestyle habits, particularly smoking and Khat chewing, were evaluated vis-à-vis MetS.

resultsThe overall prevalence of MetS in patients with schizophrenia was 21.5% (17.1% male, 29.6% female) where Low HDL-cholesterol value was the most common metabolic disorders components in both males and females subgroups. In the multivariate analysis, the positive and negative symptoms score (PANSS, AOR = 1.03, 95% CI 1.001-1.054) was associated factors with MetS.

conclusionIn Ethiopia, patients with schizophrenia were found to have higher prevalence of MetS than the general population. Physicians/health care providers should routinely screen patients with schizophrenia for MetS and initiate timely management of those who develop the syndrome to reduce the health cost from caring for NCDs, improve the patients' quality of life, and prevent premature mortality.

Indexed as

Metabolic SyndromeSchizophreniaAdultCross-Sectional StudiesEthiopiaFemaleHumansMalePrevalenceQuality of LifeRisk FactorsEthiopiaMetabolic syndromePrevalenceSchizophrenia

Identifiers

PMID34895175
PMCPMC8665491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.